Market Place
Sourcing Support
Kuva Labs To Acquire Lisata Pharma In Definitive Deal
06 Mar 2026 //
GLOBENEWSWIRE
Lisata Pharma Terminates Certepetide License Agreement With Qilu
27 Jan 2026 //
GLOBENEWSWIRE
Kuva Labs To Acquire Lisata Pharma In $4/Share Cash Deal
21 Jan 2026 //
GLOBENEWSWIRE
Lisata Therapeutics Unveils Q3 2025 Financials & Business
06 Nov 2025 //
GLOBENEWSWIRE
Lisata Therapeutics to Release Q3 Financials & Business Update
30 Oct 2025 //
GLOBENEWSWIRE
Lisata Therapeutics to Present at HC Wainwright Global Conference
02 Sep 2025 //
GLOBENEWSWIRE
Lisata Therapeutics Q2 2025 Financial Results and Update
31 Jul 2025 //
GLOBENEWSWIRE
Lisata Therapeutics Gains New Patent for Certepetide Composition
15 Jul 2025 //
GLOBENEWSWIRE
Lisata Therapeutics to Present at BIO International Convention
11 Jun 2025 //
GLOBENEWSWIRE
Lisata Therapeutics Reports Q1 2025 Results and Business Update
08 May 2025 //
GLOBENEWSWIRE
Lisata Therapeutics to Report Q1 2025 Results on May 8, 2025
01 May 2025 //
GLOBENEWSWIRE
Lisata Therapeutics Announces Research License with Catalent
15 Apr 2025 //
GLOBENEWSWIRE
Lisata Therapeutics to Present at the Investival Showcase USA
06 Mar 2025 //
GLOBENEWSWIRE
Lisata, GATC Health Partner To Use AI For Drug Development
05 Mar 2025 //
GLOBENEWSWIRE
Lisata Therapeutics Reports 2024 Financial Results and Update
27 Feb 2025 //
GLOBENEWSWIRE
Lisata To Release 2024 Results, Business Update On Feb 27
20 Feb 2025 //
GLOBENEWSWIRE
Lisata Therapeutics to Present at BIO CEO & Investor Conf 2025
05 Feb 2025 //
GLOBENEWSWIRE
Lisata Therapeutics Reports Ph 2 Data On Certepetide For Cancer
22 Jan 2025 //
GLOBENEWSWIRE
Lisata Therapeutics to Present at 2025 Sequire Investor Summit
15 Jan 2025 //
GLOBENEWSWIRE
Lisata Therapeutics Completes Enrollment in Cendifox Trial
10 Dec 2024 //
GLOBENEWSWIRE
Lisata Therapeutics, Kuva Labs Announce License for Tumor Imaging
03 Dec 2024 //
GLOBENEWSWIRE
Lisata Therapeutics Reports Q3 2024 Financial Results & Update
12 Nov 2024 //
GLOBENEWSWIRE
Lisata Therapeutics to Report Q3 2024 Financials & Updates Nov 12
06 Nov 2024 //
GLOBENEWSWIRE
Lisata & Valo Announce Preclinical Research Collaboration
06 Nov 2024 //
GLOBENEWSWIRE
Lisata Therapeutics to Attend Industry & Investor Events in Nov
31 Oct 2024 //
GLOBENEWSWIRE
Lisata To Join October 2024 Industry And Investor Events
03 Oct 2024 //
GLOBENEWSWIRE
LisataAnnounces Treatment First Patient in BOLSTER Trial Cohort
17 Sep 2024 //
GLOBENEWSWIRE
Lisata Therapeutics To Participate In September Events
09 Sep 2024 //
GLOBENEWSWIRE
Lisata Therapeutics Reports Q2 2024 Results And Business Update
12 Aug 2024 //
GLOBENEWSWIRE
Lisata Therapeutics To Report Q2 2024 Results On August 12
05 Aug 2024 //
GLOBENEWSWIRE
Haystack And Lisata Partner On Pancreatic Cancer Therapy Evaluation
18 Jul 2024 //
GLOBENEWSWIRE
Lisata Completes Enrollment In Certepetide Cholangiocarcinoma Trial
16 Jul 2024 //
GLOBENEWSWIRE
Lisata Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX Trial
13 Jun 2024 //
GLOBENEWSWIRE
Lisata Therapeutics: Participating In June 2024 Industry, Investor Events
28 May 2024 //
GLOBENEWSWIRE
Lisata Therapeutics Q1 2024 Financials And Business Update
09 May 2024 //
GLOBENEWSWIRE
Lisata to Participate in Upcoming May 2024 Industry and Investor Events
08 May 2024 //
GLOBENEWSWIRE
Lisata Q1 2024 Results, Business Update On May 9
02 May 2024 //
GLOBENEWSWIRE
Lisata and Qilu Treat First Patient in LSTA1 Pancreatic Cancer Trial
23 Apr 2024 //
GLOBENEWSWIRE
Lisata to Participate in Upcoming April 2024 Industry and Investor Events
03 Apr 2024 //
GLOBENEWSWIRE
Lisata Reports Full Year 2023 Financial Results and Provides Business Update
29 Feb 2024 //
GLOBENEWSWIRE
Lisata Therapeutics to Host Year-End 2023 Conference Call
22 Feb 2024 //
GLOBENEWSWIRE
Lisata Therapeutics to Present at BIO CEO & Investor Conference
20 Feb 2024 //
GLOBENEWSWIRE
Lisata Therapeutics to Present at the Sequire Investor Summit in Puerto Rico
18 Jan 2024 //
GLOBENEWSWIRE
Lisata Announces First Patient Treated in the Phase 2a Trial of LSTA1
17 Jan 2024 //
GLOBENEWSWIRE
Lisata Announces Publication of Case Report on Patient Treated with LSTA1
04 Jan 2024 //
GLOBENEWSWIRE
Lisata Announces Completion of Enrollment in Phase 2b Trial of LSTA1
12 Dec 2023 //
GLOBENEWSWIRE
Lisata Therapeutics to Present at NobleCon19 Investor Conference
28 Nov 2023 //
GLOBENEWSWIRE
Lisata Therapeutics Announces Participation in Upcoming Conferences in November
09 Nov 2023 //
GLOBENEWSWIRE
Lisata Reports Third Quarter 2023 Financial Results and Provides Business Update
02 Nov 2023 //
GLOBENEWSWIRE
Lisata Therapeutics to Host Third Quarter 2023 Financial Results Conference
26 Oct 2023 //
GLOBENEWSWIRE
Lisata Announces First Patient Treated in Cohort of the BOLSTER Trial of LSTA1
24 Oct 2023 //
GLOBENEWSWIRE
Lisata Therapeutics Announces Participation in Upcoming Conferences in October
28 Sep 2023 //
GLOBENEWSWIRE
Lisata Therapeutics Announces Participation in InfoSec World 2023
20 Sep 2023 //
GLOBENEWSWIRE
Lisata Therapeutics Announces First Patient Treated in BOLSTER Trial of LSTA1
12 Sep 2023 //
GLOBENEWSWIRE
Lisata Announces Outcome of Futility Analysis for its Phase 2b Trial of LSTA1
06 Sep 2023 //
GLOBENEWSWIRE
Lisata Therapeutics Announces Participation in Upcoming Conferences in September
05 Sep 2023 //
GLOBENEWSWIRE
Lisata Therapeutics Reports Second Quarter 2023 Financial Results
14 Aug 2023 //
GLOBENEWSWIRE
Lisata Therapeutics to Report Second Quarter 2023 Financial Results
07 Aug 2023 //
GLOBENEWSWIRE
Lisata Announces Retirement of Dr. Erkki Ruoslahti from Board of Directors
11 Jul 2023 //
GLOBENEWSWIRE
Lisata to Present at the GCFF Innovation and Healthcare Virtual Conference
12 Jun 2023 //
GLOBENEWSWIRE
